Annie Gardner

420 total citations
9 papers, 324 citations indexed

About

Annie Gardner is a scholar working on Infectious Diseases, Immunology and Epidemiology. According to data from OpenAlex, Annie Gardner has authored 9 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Infectious Diseases, 3 papers in Immunology and 2 papers in Epidemiology. Recurrent topics in Annie Gardner's work include Psoriasis: Treatment and Pathogenesis (3 papers), COVID-19 Clinical Research Studies (3 papers) and Urinary Tract Infections Management (1 paper). Annie Gardner is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (3 papers), COVID-19 Clinical Research Studies (3 papers) and Urinary Tract Infections Management (1 paper). Annie Gardner collaborates with scholars based in United States, Taiwan and United Kingdom. Annie Gardner's co-authors include Huaming Tan, Helen Broadhurst, Pankaj Gupta, Paul Newell, Lotus Mallbris, Diamant Thaçi, Karen Cheng, Margaret Tawadrous, James G. Krueger and Robert Wołk and has published in prestigious journals such as Clinical Infectious Diseases, The Lancet Infectious Diseases and Journal of the American Academy of Dermatology.

In The Last Decade

Annie Gardner

9 papers receiving 321 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Annie Gardner United States 6 116 92 90 88 75 9 324
Salam Abbara France 9 56 0.5× 18 0.2× 30 0.3× 26 0.3× 53 0.7× 26 235
Anke Verlinden Belgium 9 43 0.4× 21 0.2× 14 0.2× 17 0.2× 34 0.5× 20 212
Naiura Vieira Pereira Brazil 10 75 0.6× 7 0.1× 32 0.4× 28 0.3× 34 0.5× 24 302
Yıldız Yildirmak Türkiye 12 40 0.3× 19 0.2× 22 0.2× 8 0.1× 59 0.8× 31 326
Jorge Castagnino Argentina 12 147 1.3× 36 0.4× 20 0.2× 6 0.1× 135 1.8× 18 360
Nadira Duraković Croatia 9 79 0.7× 27 0.3× 25 0.3× 35 0.4× 42 0.6× 34 261
Paola Bresciani Italy 6 23 0.2× 9 0.1× 27 0.3× 49 0.6× 22 0.3× 10 275
Lin Cai China 10 113 1.0× 9 0.1× 37 0.4× 9 0.1× 87 1.2× 29 305
Adaia Albasanz‐Puig Spain 9 53 0.5× 32 0.3× 5 0.1× 51 0.6× 100 1.3× 14 325
E. K. W. Chiu China 6 59 0.5× 35 0.4× 4 0.0× 17 0.2× 263 3.5× 9 388

Countries citing papers authored by Annie Gardner

Since Specialization
Citations

This map shows the geographic impact of Annie Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annie Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annie Gardner more than expected).

Fields of papers citing papers by Annie Gardner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annie Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annie Gardner. The network helps show where Annie Gardner may publish in the future.

Co-authorship network of co-authors of Annie Gardner

This figure shows the co-authorship network connecting the top 25 collaborators of Annie Gardner. A scholar is included among the top collaborators of Annie Gardner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annie Gardner. Annie Gardner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Weinstein, Edward A., Roger Paredes, Annie Gardner, et al.. (2025). Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial. The Lancet Infectious Diseases. 25(11). 1243–1253. 3 indexed citations
2.
Hammond, Jennifer, Annie Gardner, Paula Abreu, et al.. (2024). Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial. Clinical Infectious Diseases. 80(2). 323–330. 5 indexed citations
3.
Hammond, Jennifer, Annie Gardner, Paula Abreu, et al.. (2022). 786. Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations and Other Medical Visits. Open Forum Infectious Diseases. 9(Supplement_2). 6 indexed citations
4.
Hammond, Jennifer, Annie Gardner, Paula Abreu, et al.. (2022). 1156. Sustained Alleviation and Resolution of Targeted COVID-19 Symptoms with Nirmatrelvir/Ritonavir versus Placebo. Open Forum Infectious Diseases. 9(Supplement_2). 5 indexed citations
5.
Bradley, John S., Helen Broadhurst, Karen Cheng, et al.. (2019). Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial. The Pediatric Infectious Disease Journal. 38(8). 816–824. 49 indexed citations
6.
Bradley, John S., Emmanuel Roilides, Helen Broadhurst, et al.. (2019). Safety and Efficacy of Ceftazidime–Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial. The Pediatric Infectious Disease Journal. 38(9). 920–928. 56 indexed citations
7.
Winthrop, Kevin, Neil J. Korman, William Abramovits, et al.. (2018). T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. Journal of the American Academy of Dermatology. 78(6). 1149–1155.e1. 26 indexed citations
8.
Valenzuela, Fernando, Neil J. Korman, Robert Bissonnette, et al.. (2018). Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. British Journal of Dermatology. 179(4). 853–862. 49 indexed citations
9.
Papp, Kim, James G. Krueger, Steven R. Feldman, et al.. (2016). Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. Journal of the American Academy of Dermatology. 74(5). 841–850. 125 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Salam Abbara Breakdown of academic impact, for papers by Anke Verlinden Breakdown of academic impact, for papers by Naiura Vieira Pereira Breakdown of academic impact, for papers by Yıldız Yildirmak Breakdown of academic impact, for papers by Jorge Castagnino Breakdown of academic impact, for papers by Nadira Duraković Breakdown of academic impact, for papers by Paola Bresciani Breakdown of academic impact, for papers by Lin Cai Breakdown of academic impact, for papers by Adaia Albasanz‐Puig Breakdown of academic impact, for papers by E. K. W. Chiu
Rankless by CCL
2026